CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
LY2216684 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01389752
NCT01389752Phase 1Completed
CompareCT.gov

Effect of Activated Charcoal on the Pharmacokinetics of LY2216684 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jul 8, 2011·Updated Jan 4, 2019

In Brief

A Phase 1 clinical trial evaluating LY2216684 and Activated Charcoal for Depressive Disorder, Major. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal. The study will evaluate the effect of charcoal on the absorption of LY2216684. Side effects will be documented. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last dose. Screening is required within 30 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 8, 2011
Enrollment StartJul 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.0 years ago

Interventions

LY2216684drug

Administered orally

Activated Charcoaldrug

Administered orally